Exploring the Potential Drug Target or Biomarker FAM181B: Unveiling the secrets of sequence similarity 181 member B

Target Name: FAM181B

NCBI ID: G220382

FAM181B

Other Name(s): family with sequence similarity 181 member B | Protein FAM181B | MGC33846 | Family with sequence similarity 181 member B | F181B_HUMAN

Exploring the Potential Drug Target or Biomarker FAM181B: Unveiling the secrets of sequence similarity 181 member B

The search for new drug targets and biomarkers has always been a crucial aspect of drug development. One of the promising strategies in this field is the identification of conserved sequence families, which can be used to predict the potential targets of drugs. In this article, we will focus on one such family, FAM181B, and its potential as a drug target or biomarker.

FAM181B Family

FAM181B is a conserved sequence family that contains 181 members to date. The family is characterized by the presence of a unique GXXC dinucleotide repeat in the protein sequence, which is responsible for the family's conserved secondary structure.

Drug Target Potential

The drug targeting potential of FAM181B is high due to its unique secondary structure and the conserved nature of its sequence. Several studies have suggested that FAM181B can be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the potential drug targeting of FAM181B is its conserved nature. The presence of a GXXC dinucleotide repeat in the protein sequence makes it more susceptible to drug binding, as drugs can bind to specific repeat units within the protein. Additionally, the conserved nature of the sequence may make it more stable, reducing the risk of changes in function that could render it a drug target.

Biomarker Potential

FAM181B has also been identified as a potential biomarker for various diseases. Its conserved nature and unique secondary structure make it an attractive candidate for diagnostic biomarkers.

One of the key studies that has identified FAM181B as a biomarker is the cancer-associated protein (CAP)-FAM181B experiment. This study used antibodies to detect FAM181B in various cancer samples and found that FAM181B was expressed in human cancer tissues, suggesting its potential as a biomarker for cancer.

Another study has also shown that FAM181B is expressed in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. This suggests that FAM181B may be a useful biomarker for these diseases.

Conclusion

In conclusion, the FAM181B family has a high potential as a drug target or biomarker due to its unique secondary structure and conserved nature. Further research is needed to fully understand the drug targeting and biomarker potential of FAM181B.

Protein Name: Family With Sequence Similarity 181 Member B

The "FAM181B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM181B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets